Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:brand
gptkb:drug |
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:pentamidine
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:various_countries
gptkb:European_Medicines_Agency |
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contains |
gptkb:artemether
gptkb:lumefantrine |
| gptkbp:developed_by |
gptkb:Sanofi
|
| gptkbp:formulation |
injectable solution
|
| https://www.w3.org/2000/01/rdf-schema#label |
Pentacarinat
|
| gptkbp:indication |
severe malaria
|
| gptkbp:ingredients |
gptkb:artesunate
|
| gptkbp:is_used_for |
treatment of malaria
|
| gptkbp:manager |
intravenous
|
| gptkbp:manufacturer |
gptkb:Company
|
| gptkbp:marketed_as |
the brand name Pentacarinat
|
| gptkbp:side_effect |
dizziness
headache nausea |